查看文章

Introduction: Paget’s disease of the breast is a rare disease with an incidence of 0.5 to 5%. The role of molecular markers is not well understood in this type of cancer. Therefore, we decided to study the relationship between the status of molecular markers and the patient’s prognosis and survival rates.

Materials and methods: This cross-sectional survival study was done by census sampling method. After collection, the data were entered into SPSS software version 18, and survival was assessed using Kaplan-Meier curves and Log-Rank test. P-value less than 0.05 was considered statistically significant.

Results: A total of 52 patients with a mean age of 48.89±12.51 was obtained. 57.7% of patients had right breast involvement. 44 patients (84.6%) had infiltrating ductal carcinoma (IDC) and 3 patients (5.8%) had ductal carcinoma in-situ (DCIS). Thirty-five patient (67.3%) had a positive estrogen receptor, 29 patient (55.8%) had positive progesterone receptor and 32 patients (61.5%) were HER2neu positive. 14 patients (26.9%) have died. The mean survival time was 98.08 months and the one, two, three, four, and five-years survival rate were 92%, 85%, 80%, 73%, and 69%, respectively. There was a statistically significant difference between the mean survival rate and HER2neu status. So that the mean survival in HER2neu positive patients was significantly higher than HER2neu negative patients (p< 0.002).

Conclusion: Based on the findings of the study, it can be concluded that patients with Paget’s disease have a long-life expectancy and HER2neu status is an effective factor in survival.